



CIN: U24231GJ1988PLC011652

June 01, 2021

Listing Compliance & Legal Regulatory **BSE** Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 023

Stock Code: 543233

Listing & Compliance National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra East, Mumbai 400 051

Stock Symbol: CHEMCON

Dear Sir/Madam,

Sub: Press Release - Financial Results for the quarter and financial year ended on March 31st 2021

Please find enclosed a copy of the press release with regards to the Financial Results for the quarter and financial year ended on March 31st 2021.

A copy of the same will also be uploaded on the company's website www.cscpl.com.

This is for your information and records.

Thanking you,

Yours faithfully,

For Chemcon Speciality Chemicals Limited

Shahilkumar Kapatel

Company Secretary & Compliance Officer

Membership No.: A52211



Chemcon Speciality Chemicals Limited




Q4FY21 Financial Highlights

- Revenue Stood at Rs 71.5 Cr, growth of 38% on YoY basis
- EBITDA at Rs 20.8 Cr, growth of 53% on YoY basis
- PAT at Rs 15.5 Cr, growth of 58% on YoY basis

Vadodara, May 31st, 2021: Chemcon Speciality Chemicals Limited, a leading manufacturer of specialized chemicals, such as Hexamethyldisilazane ("HMDS"), Chloromethyl Isopropyl Carbonate ("CMIC") and inorganic bromides, announced its audited financial results for the quarter and full year ended on March 31st 2021.

Financial and Operational Highlights



FY21


Q4FY20 Q4FY21

FY20

FY21

Chemcon Speciality Chemicals Limited





Commenting on the results, Mr. Kamal Aggarwal, Chairman & MD said, "We are pleased to close our financial year on a positive note led by continued business momentum in pharma chemicals & marginal recovery of bromide business during the quarter. We clocked a total operating revenue of Rs 71.5 cr for the quarter, a growth of 38% on YoY bases and profits of Rs.15.5 cr.

Our HMDS & CMIC business are operating at full capacity at 3,000 & 1,800 level respectively which is testimony of product demand. India is still a net importer of these two products and there is ample of opportunity for player like us who can become a long-term sustainable partner. We have maintained our market leadership position in this pharma chemicals. New product 4 CBC has contributed to our revenue marginally. On the other hand, products like 2,5 DHT and high purity HMDS are likely to flourish in FY22.

As stated earlier, we are enhancing our capacities of pharma intermediate chemicals at P8 & P9 which will further increase our strength with our existing product portfolio. Due to 2nd wave of pandemic, the project commercialization has been delayed by a month. We expect both this unit to commence their production by Q2FY22 & Q3FY22 respectively.

We believe that over the years, we have built strong relationship with our customers, who recognise our technical capabilities and trust our potential to deliver consistently. Post our expansion, we will be well equipped to capture new business opportunities."

Chemcon Speciality Chemicals Limited



About Chemcon Speciality Chemicals Ltd.

Incorporated in 1988, we are a manufacturer of specialized chemicals, such as HMDS & CMIC which are predominantly used in the pharmaceuticals industry and inorganic bromides, namely Calcium Bromide, Zinc Bromide and Sodium Bromide, which are predominantly used as completion fluids in the oilfields industry. In terms of production in the CY2019, we were the only manufacturer of HMDS in India and were the third largest manufacturer of HMDS worldwide. We were the largest manufacturer of CMIC in India and the second largest manufacturer of CMIC worldwide. Further, we were the only manufacturer of Zinc Bromide and the largest manufacturer of Calcium Bromide in India. We have 7 manufacturing facilities located at Manjusar near Vadodara in Gujarat. Our business presences are spread in USA, Germany, Italy, S. Korea, China, Japan, UAE, Serbia, Russia, Spain, Thailand and Malaysia. We are a ISO 9001:2015 and ISO 14001:2015 certified company for the "Manufacture and supply of pharmaceutical intermediates, silanes and oilfield chemicals".

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company:

Investor Relations Advisors:



SGA Strategic Growth Advisors

Chemcon Speciality Chemicals Ltd.

CIN - U24231GJ1988PLC011652

Mr. Rajesh Gandhi

Whole-time Director & CFO

Email ID: rajesh@cscpl.com

www.cscpl.com

Strategic Growth Advisors Pvt. Ltd.

CIN - U74140MH2010PTC204285 Mr. Shrikant Sangani / Ms. Pankti

Majithia

shrikant.sangani@sgapl.net /
pankti.majithia@sgapl.net

+91 9619595686 /+ 91 9619611096

www.sgapl.net